• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib.

作者信息

Yun Hwan-Jung, Seo Young Joon, Lee Hyo Jin

机构信息

Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.

Department of Dermatology, Chungnam National University School of Medicine, Daejeon, Korea.

出版信息

Ann Dermatol. 2015 Dec;27(6):791-2. doi: 10.5021/ad.2015.27.6.791. Epub 2015 Dec 7.

DOI:10.5021/ad.2015.27.6.791
PMID:26719663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4695446/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ae/4695446/cabf1d7ffc42/ad-27-791-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ae/4695446/cabf1d7ffc42/ad-27-791-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ae/4695446/cabf1d7ffc42/ad-27-791-g001.jpg

相似文献

1
Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib.白发与多靶点受体酪氨酸激酶抑制剂帕唑帕尼有关。
Ann Dermatol. 2015 Dec;27(6):791-2. doi: 10.5021/ad.2015.27.6.791. Epub 2015 Dec 7.
2
Rapid hair depigmentation in patient treated with pazopanib.接受帕唑帕尼治疗的患者出现快速毛发色素脱失。
BMJ Case Rep. 2018 Aug 23;2018:bcr-2018-224209. doi: 10.1136/bcr-2018-224209.
3
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.帕唑帕尼：一种新型多靶点酪氨酸激酶抑制剂。
Curr Oncol Rep. 2007 Mar;9(2):115-9. doi: 10.1007/s11912-007-0007-2.
4
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.帕唑帕尼，一种用于治疗肾细胞癌的强效口服小分子多靶点酪氨酸激酶抑制剂。
Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253.
5
Polypharmacology of sulfonamides: pazopanib, a multitargeted receptor tyrosine kinase inhibitor in clinical use, potently inhibits several mammalian carbonic anhydrases.磺胺类药物的多药理学：帕唑帕尼，一种临床应用的多靶点受体酪氨酸激酶抑制剂，能有效抑制几种哺乳动物碳酸酐酶。
Chem Commun (Camb). 2012 Aug 25;48(66):8177-9. doi: 10.1039/c2cc33415a. Epub 2012 Jun 26.
6
Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.帕唑帕尼：一种用于治疗肾细胞癌的口服多靶点酪氨酸激酶抑制剂。
Ann Pharmacother. 2010 Jun;44(6):1054-60. doi: 10.1345/aph.1M251. Epub 2010 Apr 20.
7
Pazopanib in the management of advanced soft tissue sarcomas.帕唑帕尼用于晚期软组织肉瘤的治疗
Ther Clin Risk Manag. 2016 Jun 9;12:941-55. doi: 10.2147/TCRM.S84792. eCollection 2016.
8
Chronic active hepatitis induced by Pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: A case report.帕唑帕尼诱发慢性活动性肝炎，酷似复发性软组织肉瘤患者的富血管性肝转移：一例报告
Oncol Lett. 2018 Sep;16(3):4043-4048. doi: 10.3892/ol.2018.9114. Epub 2018 Jul 10.
9
Pazopanib and pancreatic toxicity: a case report.帕唑帕尼与胰腺毒性：一例报告
BMC Res Notes. 2015 May 14;8:196. doi: 10.1186/s13104-015-1154-4.
10
Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience.帕唑帕尼治疗骨肉瘤：临床经验
Transl Oncol. 2020 Feb;13(2):295-299. doi: 10.1016/j.tranon.2019.12.001. Epub 2019 Dec 23.

本文引用的文献

1
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.帕唑帕尼对比舒尼替尼用于转移性肾细胞癌。
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
2
Pazopanib for the treatment of renal cancer.帕唑帕尼治疗肾癌。
Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7.
3
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.帕唑帕尼治疗局部晚期或转移性肾细胞癌：一项随机 III 期试验结果。
J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25.
4
Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.舒尼替尼与因临时抑制c-KIT导致的周期性毛发色素脱失。
Arch Dermatol. 2008 Nov;144(11):1525-6. doi: 10.1001/archderm.144.11.1525.
5
Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor.
Arch Dermatol. 2006 Nov;142(11):1477-9. doi: 10.1001/archderm.142.11.1477.
6
Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
J Pharmacol Exp Ther. 2003 Nov;307(2):476-80. doi: 10.1124/jpet.103.052530. Epub 2003 Sep 9.